Eli Lilly files six lawsuits against sellers of black-market retatrutide

Eli Lilly filed six federal lawsuits on August 12, 2026 against US businesses it accuses of selling black-market versions of retatrutide, its experimental "triple-agonist" obesity drug that no regulator anywhere in the world has approved ^[1][6]. The defendants are not just anonymous internet vendors: they include a medical spa, a compounding pharmacy and four sellers that label products "research use only" ^[6].

The named defendants are Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide ^[1][5]. Lilly's release lists one case in the Northern District of California and five across Texas federal courts ^[1]; a law firm analysis described all six as filed in four federal district courts in Texas ^[6]. In each case Lilly asks for a permanent injunction barring the defendant from making, marketing, distributing or selling any product containing or claiming to contain retatrutide, plus disgorgement of profits and attorney's fees ^[6].

The lawsuits are one piece of a larger campaign. Lilly says it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and professional licensing boards, and has reported more than 14,000 websites, ads, social media posts and product listings in over 100 countries ^[1][2]. The company is also pressing social media and e-commerce platforms, credit card companies, payment processors and shipping carriers to cut off the sellers' business infrastructure ^[1][3].

"What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk," said David A. Hyman, M.D., Lilly's chief medical officer ^[1].

What the sources say about the risk

Retatrutide targets three receptors — GLP-1, GIP and glucagon — and remains in Phase 3 trials ^[1][6]. Reported trial results differ across sources: the Washington Post reported that in May, Lilly said trial patients lost an average of 28% of body weight, versus 21% with its approved drug Zepbound (tirzepatide) ^[5], while pharmaphorum cited up to 24% weight loss over 48 weeks ^[3]. Either way, the headlines have driven demand that outpaces approval.

The FDA has said sales of unapproved retatrutide to consumers are illegal, that retatrutide cannot lawfully be compounded, and that "research-use only" products "are of unknown quality and may be harmful to [consumers'] health" ^[1]. Analysis of seized counterfeits has found incorrect dosages ranging from zero to overdoses, and entirely different active ingredients such as insulin, which could be life-threatening; many are believed made in non-sterile conditions ^[3]. The UK's MHRA seized 2,000 pen injectors purporting to contain retatrutide or tirzepatide, plus tens of thousands of empty pens, from a single site last October ^[3]. There have been reports of serious side effects, including liver failure, among people sourcing the drug this way ^[3].

Why it matters for patients

The practical takeaway from these filings is that a clinic setting, a white coat or a pharmacy label does not mean a retatrutide product is legal or tested. CBS News found dozens of professional clinics advertising the drug along with compounding pharmacies, including Striker Pharmacy, one of the entities Lilly is now suing ^[2]. Lilly's complaint against Lone Star Peptide points to a dosage calculator aimed at patients on its website and TikTok videos in which its chief executive addresses "you guys sitting at home" ^[5].

According to one legal analysis, the only lawful ways to get retatrutide in the US right now are through Lilly-sponsored clinical trials or, in narrow circumstances, the FDA's expanded access framework ^[6]. Because no version is approved, there is no verified dosing, no pharmacy-level quality control and no adverse-event reporting system behind what black-market sellers ship.

One caution: these are Lilly's allegations, not proven findings. Legendary Peptides had no immediate comment, and representatives for the other five companies did not immediately respond to requests for comment ^[2][5].

What happens next

Sources disagree on timing. The Washington Post reported Lilly is expected to submit retatrutide to the FDA by the end of 2026, with the earliest possible market entry in 2027 ^[5]. BioPharma Dive and a legal analysis both said Lilly does not plan to file until 2027 ^[2][6]. No court dates or rulings in the six cases have been reported yet.